Edwards Lifesciences Corporation $EW Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2,124.7% in the fourth quarter, Holdings Channel reports. The firm owned 641,869 shares of the medical research company’s stock after acquiring an additional 613,017 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Edwards Lifesciences were worth $54,771,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Level Four Advisory Services LLC raised its holdings in shares of Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after buying an additional 119 shares during the period. Colonial Trust Co SC boosted its holdings in Edwards Lifesciences by 0.4% in the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after acquiring an additional 120 shares during the period. Howard Capital Management Inc. grew its position in Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after acquiring an additional 132 shares in the last quarter. Alpine Bank Wealth Management raised its stake in shares of Edwards Lifesciences by 10.7% during the third quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 135 shares during the period. Finally, B. Riley Wealth Advisors Inc. raised its stake in shares of Edwards Lifesciences by 3.7% during the third quarter. B. Riley Wealth Advisors Inc. now owns 4,229 shares of the medical research company’s stock valued at $329,000 after purchasing an additional 151 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on EW. Piper Sandler restated an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Barclays reissued an “overweight” rating and issued a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research report on Monday, January 12th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Trading Up 1.7%

NYSE EW opened at $81.46 on Thursday. The company has a market capitalization of $46.97 billion, a price-to-earnings ratio of 44.52, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company’s fifty day moving average price is $81.78 and its two-hundred day moving average price is $81.72.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same quarter last year, the company posted $0.59 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the sale, the vice president owned 21,266 shares in the company, valued at $1,827,387.38. This represents a 34.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,897,284.92. This represents a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 61,718 shares of company stock worth $5,236,281 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.